NeoGenomicsNEO
Recorded

NeoGenomics Stephens Annual Investment Conference

Review the key takeaways and the transcript of this earnings call.

PeriodFY 0Duration35 minParticipants4

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Mason CarricoDiagnostics and Med Tech Analyst

You guys good to go?

Tony ZookCEO

Yeah, sure. Yeah. Absolutely. Good to go.

Mason CarricoDiagnostics and Med Tech Analyst

All right. We'll go ahead and get started here. Welcome to day one of the Stephens Conference. Mason Carrico, I'm the Diagnostics and Med Tech Analyst here. Happy to have the Neo team with us here today. We've got Tony Zook, CEO, Warren Stone, COO, soon to be CEO, and Abhishek Jain, CFO. First, thank you guys for being here.

Tony ZookCEO

Cheers. Maybe just start off, just give us a quick overview of Q3, main takeaways, highlights, what we should be thinking about coming out of the print.

Tony ZookCEO

I will kick us off, and if I miss anything, Warren and Abhishek can jump in. I would say, Mason Carrico, all in all, it was a really strong quarter for us, Q3, as we head into Q4. Our clinical business, which makes up about 93% of our business, that was up 13%. It was driven in large part by NGS. Our NGS business, which I think is probably still not a well-appreciated part of the Neo story. It is a third of our business, and it grew 29%. So that is a business that is $250 million growing at a really nice clip. That, in turn, helped contribute, because of volume, that 29% was driven by 17% volume growth, so very durable performance on the NGS side. And our large panels were also up over 25%.

Tony ZookCEO

When we look consistently across the NGS portfolio, we see really good underlying trends there. Our AUP was what we thought it would be, slightly higher, in fact, up at around 11%, so we always thought we could get upper single digit, so we beat those expectations for ourselves. We initiated the rollout in MRD for our IO indication for RaDaR ST, so that was a pivotal moment for us to lay that foundation. We saw a very robust gross margin expansion, so we are clicking on all cylinders relative to finding the efficiencies that we thought we could find across the business, and that translated into solid EBITDA growth as well. And the underlying volume was even better than we expected. Remember, we had to go through that kind of high volume, low value contract, and we were kind of thought flat to up a little bit.

Tony ZookCEO

It was up 2%, and the underlying was up 3%. So we think we are really well positioned all in all, and it was a really good, strong quarter for us.

Warren StoneCOO

I think maybe just two additional things. I mean, we saw a 53% improvement year-over-year in adjusted EBITDA.

Tony ZookCEO

Yeah. Strong bottom line improvement, and I think with that, we also raised the guide.

Tony ZookCEO

Yeah. I think that rounds out what Tony said.

Warren StoneCOO

We felt quarter three was a strong quarter for us.

Mason CarricoDiagnostics and Med Tech Analyst

Mm-hmm. Maybe on the point of NGS, it accelerated 29%. I think it may have been blended 26% or something like that in the first half.

Tony ZookCEO

Yeah. The full year guide's guiding to greater than 25% for the full year, so maybe that reads like somewhat of a step down in Q4.

Mason CarricoDiagnostics and Med Tech Analyst

Maybe give us some color, I guess, on how you're thinking about Q4. Why not carry a higher rate forward? I get that it's more than 25%.

Tony ZookCEO

Yeah. How much of that is conservatism versus something you're seeing?

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day